{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:21:14Z","timestamp":1762100474796},"reference-count":56,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,3,16]],"date-time":"2006-03-16T00:00:00Z","timestamp":1142467200000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2006,3]]},"abstract":"<jats:p><jats:bold>Abstract:<\/jats:bold> Laboratory studies and studies in normal volunteers have suggested a possible adverse interaction between aspirin and ibuprofen. It is thought that ibuprofen prevents aspirin from gaining access to platelet cyclooxygenase. Following the publication of these studies, a number of observational and other studies have been published. We review these studies identified by structured searching of Medline and Pubmed databases. We conclude that on the balance of probabilities that ibuprofen is more likely to interact with aspirin than not. This interaction is more likely in those who take ibuprofen chronically and is more important in those at high cardiovascular risk. Thus, a reasonable strategy might be to advise aspirin takers to avoid chronic ibuprofen.<\/jats:p>","DOI":"10.1111\/j.1742-7843.2006.pto_371.x","type":"journal-article","created":{"date-parts":[[2006,3,16]],"date-time":"2006-03-16T15:30:37Z","timestamp":1142523037000},"page":"275-280","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Is there an Interaction between the Cardiovascular Protective Effects of Low\u2010Dose Aspirin and Ibuprofen?"],"prefix":"10.1111","volume":"98","author":[{"given":"Thomas M.","family":"MacDonald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,3,16]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"24","article-title":"Naproxen and celecoxib suspended in Alzheimer prevention trial","volume":"19","author":"Anonymous","year":"2005","journal-title":"WHO Drug Information"},{"key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","volume":"308","author":"Antiplatelet Trialists Collaboration","year":"1994","journal-title":"Brit. Med. J."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7329.71"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021735"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.307.6908.846"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/14.7.951"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.01.045"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00019501-199809040-00007"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa003199"},{"key":"e_1_2_8_11_1","first-page":"38","article-title":"Experiences with aspirin (Acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis","volume":"75","author":"Craven L. L.","year":"1953","journal-title":"Mississippi Valley Med. J."},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7427.1322"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.01.001"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000013777.21160.07"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16894-3"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.25.4.503.61021"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200007000-00004"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000132491.96623.04"},{"key":"e_1_2_8_19_1","first-page":"522","article-title":"CLASS clarification: reaffirms the medical importance of the analyses and results","volume":"327","author":"Geis G. S.","year":"2003","journal-title":"Brit. Med. J."},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17864-7"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000015422.86569.52"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-136-2-200201150-00016"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(01)00461-9"},{"key":"e_1_2_8_24_1","first-page":"1589","article-title":"Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction","volume":"32","author":"Hudson M.","year":"2005","journal-title":"J. Rheumatol."},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.9.978"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7427.1298"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.08.064"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.121270"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000087593.07533.9B"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp012672"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0090-6980(82)90123-X"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12509-3"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.4.481"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01979.x"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38456.676806.8F"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.251543298"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.8.852"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2004.02850.x"},{"key":"e_1_2_8_39_1","first-page":"917","article-title":"Antiplatelet therapy and atherosclerotic events. Risks and patients' values need to be included in decision about aspirin for prevention of coronary heart disease","volume":"324","author":"Pignone M.","year":"2002","journal-title":"Brit. Med. J."},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.329.7456.15"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.10.1111"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.3.4.383"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07370-1"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050613"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.72.8.3073"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/heart.85.3.265"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16893-1"},{"key":"e_1_2_8_48_1","unstructured":"Scotland's Health on the Web: http:www.show.scot.nhs.ukisdprimarycarepservicespcarepsdispensing05.htm(checked 12\/8\/05) ."},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.01.049"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-4-199508150-00001"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.10.1099"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000127578.21885.3E"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.02.034"},{"key":"e_1_2_8_54_1","first-page":"233","article-title":"Thrombosis prevention trial: randomised trial of low\u2010intensity oral anticoagulation with warfarin and low\u2010dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework","volume":"35","year":"1998","journal-title":"Lancet"},{"key":"e_1_2_8_55_1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0049-3848(03)00379-7","article-title":"The mechanism of action of aspirin","volume":"15","author":"Vane J. R.","year":"2003","journal-title":"Thromb. Res."},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67462-4"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.19.2197"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-7843.2006.pto_371.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1742-7843.2006.pto_371.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T20:45:39Z","timestamp":1696970739000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-7843.2006.pto_371.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["10.1111\/j.1742-7843.2006.pto_371.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1742-7843.2006.pto_371.x","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3]]},"assertion":[{"value":"2006-03-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}